VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Gulley on Checkpoint Inhibitors in Bladder Cancer

James L. Gulley, MD, PhD
Published: Monday, Mar 14, 2016



James L. Gulley, MD, PhD, Chief, Genitourinary Malignancies Branch, Senior Investigator, Head, Immunotherapy Section, Director, Medical Oncology Service, CCR Office of the Clinical Director, National Cancer Institute, discusses checkpoint inhibitors in bladder cancer.

Checkpoint inhibitors are currently being investigated in a wide range of clinical trials in bladder cancer. Data has suggested significant activity of atezolizumab, pembrolizumab, avelumab in patients with metastatic bladder cancer.

Now that activity is being seen, further investigation is needed to determine if these agents should be used as single agents or in earlier settings, says Gulley.



James L. Gulley, MD, PhD, Chief, Genitourinary Malignancies Branch, Senior Investigator, Head, Immunotherapy Section, Director, Medical Oncology Service, CCR Office of the Clinical Director, National Cancer Institute, discusses checkpoint inhibitors in bladder cancer.

Checkpoint inhibitors are currently being investigated in a wide range of clinical trials in bladder cancer. Data has suggested significant activity of atezolizumab, pembrolizumab, avelumab in patients with metastatic bladder cancer.

Now that activity is being seen, further investigation is needed to determine if these agents should be used as single agents or in earlier settings, says Gulley.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x